Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study

[1]  Joe Y. Chang,et al.  Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  M. Tiemann,et al.  TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy—EGFR mutated non-small cell lung cancer IV patients treated with osimertinib , 2022, Translational lung cancer research.

[3]  J. Shih,et al.  RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability , 2021, Drug Safety.

[4]  Ying Cheng,et al.  Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes , 2021, Nature Communications.

[5]  R. Guo,et al.  Concurrent use of anlotinib overcomes acquired resistance to EGFR‐TKI in patients with advanced EGFR‐mutant non‐small cell lung cancer , 2021, Thoracic cancer.

[6]  M. Schlesner,et al.  Combinations of Low-Frequency Genetic Variants Might Predispose to Familial Pancreatic Cancer , 2021, Journal of personalized medicine.

[7]  F. Iacovelli,et al.  Post Zygotic, Somatic, Deletion in KERATIN 1 V1 Domain Generates Structural Alteration of the K1/K10 Dimer, Producing a Monolateral Palmar Epidermolytic Nevus , 2021, International journal of molecular sciences.

[8]  Chengping Hu,et al.  Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant non-small cell lung cancer: the phase III ACTIVE study (CTONG1706). , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  S. Novello,et al.  RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis. , 2021, Cancer treatment and research communications.

[10]  Ying Cheng,et al.  Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study , 2021, Targeted Oncology.

[11]  H. Qin,et al.  Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study , 2020, Cancer management and research.

[12]  Z. Lou,et al.  Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC , 2020, Clinical Cancer Research.

[13]  J. Shih,et al.  Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[14]  X. Kong,et al.  Genetic analysis of 1051 Chinese families with Duchenne/Becker Muscular Dystrophy , 2019, BMC Medical Genetics.

[15]  J. Heymach,et al.  Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy , 2019, Nature Reviews Cancer.

[16]  R. Guo,et al.  Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer , 2019, Oncology letters.

[17]  A. Gemma,et al.  Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. , 2019, The Lancet. Oncology.

[18]  R. Rosell,et al.  Co-mutations in EGFR driven non-small cell lung cancer , 2019, EBioMedicine.

[19]  Li Zhang,et al.  Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer , 2019, EBioMedicine.

[20]  Xin-Zu Chen.  Anlotinib for Refractory Advanced Non-Small Cell Lung Cancer in China. , 2019, JAMA oncology.

[21]  F. Ahmad,et al.  Investigation of deleterious effects of nsSNPs in the POT1 gene: a structural genomics‐based approach to understand the mechanism of cancer development , 2018, Journal of cellular biochemistry.

[22]  Ying Cheng,et al.  Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial , 2018, JAMA oncology.

[23]  Liang Cheng,et al.  Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non‐medullary thyroid carcinoma , 2018, International journal of cancer.

[24]  Ying Cheng,et al.  Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. , 2018, The Lancet. Respiratory medicine.

[25]  C. Langer,et al.  Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. , 2018, JCO precision oncology.

[26]  Y. Huang,et al.  Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non–Small Cell Lung Cancer , 2018, JAMA oncology.

[27]  Ying Cheng,et al.  Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer , 2018 .

[28]  S. O'toole,et al.  EGFR–Co‐Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  Matteo Canale,et al.  Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors , 2016, Clinical Cancer Research.

[30]  Gill Bejerano,et al.  M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity , 2016, Nature Genetics.

[31]  Trevor Hastie,et al.  REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. , 2016, American journal of human genetics.

[32]  B. Han,et al.  First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE). , 2016 .

[33]  D. Costa,et al.  Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches , 2016, Therapeutic advances in respiratory disease.

[34]  K. Yoshida,et al.  Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase II study. , 2015, Translational lung cancer research.

[35]  R. Rosell,et al.  Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer , 2014, Clinical Cancer Research.

[36]  Jana Marie Schwarz,et al.  MutationTaster2: mutation prediction for the deep-sequencing age , 2014, Nature Methods.

[37]  C. Langer.  Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  L. Tanoue,et al.  Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.

[39]  J. Miller,et al.  Predicting the Functional Effect of Amino Acid Substitutions and Indels , 2012, PloS one.

[40]  Jana Marie Schwarz,et al.  MutationTaster evaluates disease-causing potential of sequence alterations , 2010, Nature Methods.

[41]  S Senan,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[43]  J. Manola,et al.  TP53 mutations and survival in squamous-cell carcinoma of the head and neck. , 2007, The New England journal of medicine.

[44]  Ying Cheng,et al.  Osimertinib versus Standard of Care EGFR TKI as First‐Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.